Search

Background: Lichen Planus (LP) is a dermatological disorder characterized by violaceous papules that affect the cutaneous region, nails, scalp, and mucous membranes. Current molecular and clinical studies point to the Janus Kinase-signal transducer and activator of transcription (JAK-STAT) pathway as a potential effector of LP pathology. Objective: This systematic review summarizes the current reported literature outcomes for patients receiving JAK inhibitors to treat LP. Methods: MEDLINE and Embase were searched on 16 October, 2022, and 15 original articles were included, with 56 LP patients. Results: (mean age: 54.5 years, range: 26-81 years, male: 26.8%). The treatment outcomes were included for the following JAK inhibitors: tofacitinib (n = 30), baricitinib (n = 16), ruxolitinib (n = 12), and upadacitinib (n = 2). Patient outcomes were classified into complete resolution, partial resolution, and no resolution. Patients achieving complete resolution represented 25% (n = 4/16) in the baricitinib group, 10% (n = 3/30) in the tofacitinib group, 16.7% (n = 2/12) in the ruxolitinib group, and 100% (2/2) in the upadacitinib group. Partial resolution patients represented 31.3% (n = 5/16) of baricitinib patients, 60% (n = 18/30) of tofacitinib patients, and 83% (n = 10/12) of ruxolitinib patients. 43.8% (n = 7/16) of baricitinib patients and 10% (n = 9/30) of tofacitinib patients had no resolution of lesions. Conclusion: This review also highlights the significance of utilizing a uniform outcome measure for LP, as it aids in reporting more generalizable results, reduces reporting bias, and ultimately lead to improved clinical outcomes for LP patients. [ABSTRACT FROM AUTHOR]

This document is a letter to the editor discussing the real-world effectiveness and safety of risankizumab in adult patients with plaque psoriasis. The authors conducted a 16-week international multicenter retrospective cohort study to evaluate the outcomes of risankizumab treatment. The study included 388 patients, and after 16 weeks of treatment, 75% of patients achieved a 90% improvement in the Psoriasis Area and Severity Index (PASI90) score or a Physician Global Assessment (PGA) score of 0 or 1. Adverse events were infrequent, and treatment discontinuation events were uncommon. The study suggests that the effectiveness of risankizumab in real-world patients is comparable to the efficacy observed in phase III randomized controlled trials. However, further studies with control populations are needed to confirm these findings. [Extracted from the article]

The systematic review in the Journal of Cutaneous Medicine & Surgery examines the outcomes of systemic biologic therapy for refractory chronic urticaria, a challenging inflammatory skin condition. Omalizumab was the most common systemic biologic used, achieving complete resolution in 73.3% of cases. The review highlights the effectiveness of systemic biologics, particularly omalizumab and ligelizumab, in treating refractory chronic urticaria, although further studies are needed to confirm these findings. [Extracted from the article]

This document is a letter to the editor discussing the development of immune checkpoint inhibitors (ICIs) and their association with cutaneous granulomatous reactions (GD). The authors conducted a systematic review of reports on ICI-associated GD to better understand the clinical implications. They found that GDs observed in patients treated with ICIs included sarcoid-like granulomas, interstitial granulomatous dermatitis, granuloma annulare, granulomatous panniculitis, and foreign-body granuloma. The review also highlighted the importance of timely biopsy to confirm the etiology of radiological findings and offered management considerations for dermatologists and dermatopathologists. [Extracted from the article]